alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>

<ARTICLE> BD
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   6-MOS                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998             DEC-31-1997
<PERIOD-START>                             JAN-01-1998             JAN-01-1997
<PERIOD-END>                               JUN-30-1998             JUN-30-1997
<CASH>                                               0                       0
<RECEIVABLES>                                2,260,588               2,218,173
<SECURITIES-RESALE>                                  0                       0
<SECURITIES-BORROWED>                                0                       0
<INSTRUMENTS-OWNED>                          9,476,703               8,775,472
<PP&E>                                               0                       0
<TOTAL-ASSETS>                              11,737,291              10,993,645
<SHORT-TERM>                                         0                       0
<PAYABLES>                                      85,922                 231,030
<REPOS-SOLD>                                         0                       0
<SECURITIES-LOANED>                                  0                       0
<INSTRUMENTS-SOLD>                                   0                       0
<LONG-TERM>                                          0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                             0                       0
<OTHER-SE>                                  11,651,369              10,762,615
<TOTAL-LIABILITY-AND-EQUITY>                11,737,291              10,993,645
<TRADING-REVENUE>                            1,205,980               1,289,030
<INTEREST-DIVIDENDS>                           308,014                 277,758
<COMMISSIONS>                                  176,539                 142,118
<INVESTMENT-BANKING-REVENUES>                        0                       0
<FEE-REVENUE>                                        0                       0
<INTEREST-EXPENSE>                                   0                       0
<COMPENSATION>                                       0                       0
<INCOME-PRETAX>                              1,337,455               1,424,670
<INCOME-PRE-EXTRAORDINARY>                   1,337,455               1,424,670
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                 1,337,455               1,424,670
<EPS-PRIMARY>                                    34.14                   34.10
<EPS-DILUTED>                                    34.14                   34.10
        

</TABLE>
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1148 Bacterially-derived carbohydrase enzyme preparation. ( a ) Bacterially-derived carbohydrase enzyme preparation is obtained from the culture filtrate resulting from a pure culture fermentation of a nonpathogenic and nontoxigenic strain of *Bacillus subtilis* or *B. amyloliquefaciens.* The preparation is characterized by the presence of the enzymes α-amylase (EC 3.2.1.1) and β-glucanase (EC 3.2.1.6), which catalyze the hydrolysis of *O*-glycosyl bonds in carbohydrates.
( b ) The ingredient meets the general requirements and additional requirements in the monograph on enzyme preparations in the Food Chemicals Codex, 4th ed. (1996), pp. 128-135, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .* In addition, antibiotic activity is absent in the enzyme preparation when determined by an appropriate validated method such as the method “Determination of antibiotic activity” in the Compendium of Food Additive Specifications, vol. 2, Joint FAO/WHO Expert Committee on Food Additives (JECFA), Food and Agriculture Organization of the United Nations, Rome, 1992. Copies are available from Bernan Associates, 4611-F Assembly Dr., Lanham, MD 20706, or from The United Nations Bookshop, General Assembly Bldg., rm. 32, New York, NY 10017, or by inquiries sent to *http://www.fao.org .* Copies may be examined at the Center for Food Safety and Applied Nutrition's Library, 5001 Campus Dr., College Park, MD 20740.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as GRAS as a direct food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme as defined in § 170.3(o)(9) of this chapter to hydrolyze polysaccharides (e.g., starch).
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
[64 FR 19894, Apr. 23, 1999, as amended at 81 FR 5595, Feb. 3, 2016; 88 FR 17724, Mar. 24, 2023]
Introduction: Status 

Introduction: Status 

Re-Evaluation of the 

Evaluation of the 

Health Effects of Atr

Health Effects of Atr

An

Senior Scientist, Health 

Office of Pes

lowit
Atrazine Human Health Re Atrazine Human Health Re-Eva

Eva

z Risk Management Goal – Prote

Health From Unreasonable Ris

• Hazard Assessment: Determine m

lifestages and endpoints, associatof exposure, and dose-response re

• Exposure Assessment: Determine 

in drinking water with adequate co
February 

2010

April 

2010

September 

2010 

Epidemiology studies: noncancer Integrated weigof the evidence hazard characterization for non-cancer

Frequency of atrazine monitoring in drinking water sources (proposed approaches)

Frequency of atrazine monitoring in drinking water sources (updateanalyses)

Preliminary evaluation of in 

vitro & in vivo

laboratory studies (cancer & noncancer)

Incorporating epidemiology studies and human health incident data in risk assessmentTwo atrazine case studies

Atrazine SAP Meetings: Hu

Atrazine SAP Meetings: Hu
Atrazine Human Hazard Re Atrazine Human Hazard Re-Ev

Ev

z Objective & thorough review of new scie

 Conduct Mode of Action (MOA) framework a

• Key events / pathway of toxicity • Dose-response & temporal concordance • Life stage susceptibility, and • Human relevance

 Determine duration of toxicological concern Characterize areas of confidence and uncert Integrate experimental toxicology with epide

weight-of-evidence (WOE) assessment of haand dose-response relationships
Atrazine Human Exposure Re Atrazine Human Exposure Re-

Drinking Water Drinking Water

z Estimates of exposure that match 

duration of toxicological concern, e

 Single day peaks Multi-day averages (e.g., 3, 7, 90 day

z Understanding of confidence in the 

 Temporal & spatial variability  Statistical approaches for interpolatin

data
Atrazine Drinking Water Expos

Atrazine Drinking Water Expos
After Re After Re-Evaluation Effor

Evaluation Effor

z In light of the new science and 

from the Panel, the Agency wildetermine: 

 If the risk assessment for atrazin

revised. 

 Whether the drinking water mon

frequency requirements should b
Exhibit 32



                        President's Written Certification
                             Of Financial Statements
                       Pursuant to 18 U.S.C. Statute 1350



     Pursuant to 18 U.S.C. Statute 1350, as adopted pursuant to Section 907 of
the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies in his capacity
as president of Ridgefield Acquisition Corp. (the "Company") that

     (a)  the Quarterly Report of the Company on Form 10-Q for the period Ended
          March 31, 2009 fully complies with the requirements of Section 13(a)
          of the Securities Exchange Act of 1934, and

     (b)  the information contained in such report fairly presents, in all
          material respects, the financial condition of the Company at the end
          of such period and the results of operations of the Company for such
          period.


Dated: May 14, 2009

                                            /s/ Steven N. Bronson
                                            ----------------------------------
                                            Steven N. Bronson, President
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE 
FINANCIAL STATEMENTS OF CYBEX COMPUTER PRODUCTS CORPORATION FOR THE YEAR
ENDED MAR-31-1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH 
FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED> 
<CIK> 0000946360
<NAME> CYBEX COMPUTER PRODUCTS CORPORATION
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAR-31-1997
<PERIOD-START>                             APR-01-1996
<PERIOD-END>                               MAR-31-1997
<EXCHANGE-RATE>                                      1
<CASH>                                           2,424
<SECURITIES>                                    40,885
<RECEIVABLES>                                    5,761
<ALLOWANCES>                                       350
<INVENTORY>                                      3,835
<CURRENT-ASSETS>                                51,719
<PP&E>                                           3,294
<DEPRECIATION>                                     871
<TOTAL-ASSETS>                                  56,567
<CURRENT-LIABILITIES>                           11,227
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             9
<OTHER-SE>                                      50,249
<TOTAL-LIABILITY-AND-EQUITY>                    56,567
<SALES>                                         34,568
<TOTAL-REVENUES>                                34,568
<CGS>                                           16,409
<TOTAL-COSTS>                                   16,409
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   219
<INTEREST-EXPENSE>                                   4
<INCOME-PRETAX>                                  9,233
<INCOME-TAX>                                     3,393
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     5,940
<EPS-PRIMARY>                                     0.71
<EPS-DILUTED>                                     0.70
<FN>
WE HAVE CALCULATED EARNINGS PER SHARE AMOUNTS IN ACCORDANCE WITH FAS 128
"EARNINGS PER SHARE." WE HAVE ENTERED BASIC AND DILUTED AMOUNTS IN PLACE OF
PRIMARY AND FULLY DILUTED, RESPECTIVELY, AND REFLECT THE THREE-FOR-TWO STOCK
DIVIDEND EFFECTIVE APRIL 10, 1998.
</FN>
        

</TABLE>
John R. Kasich, Governor 

Mary Taylor, Lt. Governor 

Craig W. Butler, Director 

SEP 5 2014 

Susan Hedman 

Regional Administrator 

USEPA Region 5 

77 West Jackson Boulevard 

Mail Code: R-19J 

Chicago, IL 60604-3507 

RE: Withdrawal of Request for SIP Approval of paragraph (B)(1)(b) of OAC Rule 3745-

17-03 Regarding an Alternative Procedure for Determining Compliance with Ohio's 

Opacity limitation. 

Dear Ms. Hedman, 

On June 4, 2003, Ohio submitted a State Implementation Plan (SIP) request regarding 

incorporation of changes to Ohio Administrative Code (OAC) Chapter 17 for the regulation 

of particulate matter. On June 27, 2005, U.S. EPA proposed disapproval of a portion of 

OAC Rule 3745-17-03; specifically regarding provisions for the use of continuous opacity 

monitoring (COMs) measurements to determine compliance with Ohio's 20% opacity 

limitation (currently contained within paragraph (B)(1 )(b)). Years passed without any further 

action on the 2005 proposed disapproval. Then on June 26, 2014, U.S. EPA noticed a 

supplemental proposal specifically requesting comments on whether any events have 

occurred or any policy considerations have occurred, since the 2005 proposed disapproval 

that should be considered as U.S. EPA takes final action on the 2005 proposed disapproval. 

At this time, Ohio EPA would like to request withdrawal of our June 4, 2003 request to 

incorporate paragraph (B)(1)(b) into Ohio's SIP. Substantial time has passed since our 

June 4, 2003 submittal and circumstances have changed. This SIP revision request is no 

longer necessary at this time. Ohio EPA will be pursuing more relevant rule changes based 

on current circumstances for facilities within the State. 

Sincerely, 

r 

~~Butler ~iS.'=-- Director, Ohio EPA 

Cc: Bob Hodanbosi, Chief, Division of Air Pollution Control, Ohio EPA 

Douglas Aburano, Chief, Attainment Planning and Maintenance Section, U.S.EPA 

50 West Town Street,_ Suite 700 (/J P.O. Box 1049 "'Columbus, OH 43216-1.049 

www.epa.ohio.gov • (614) 644-3020 • (614) 644-3184 (fax)
<PAGE>   1

December 15, 1998



The Board of Directors of                                            EXHIBIT 5.1
United Security Bancorporation
Spokane, Washington


        RE:    LEGAL OPINION REGARDING VALIDITY OF SECURITIES OFFERED

Gentlemen:

        As you know, we are acting as counsel for United Security
Bancorporation, a Washington corporation and registered bank holding company
("USBN"), in connection with the registration under the Securities Act of 1933,
as amended ("Act"), of a maximum of 1,900,000 shares of USBN's common stock, no
par value per share ("Shares"). A Registration Statement on Form S-4
("Registration Statement") is being filed with the Securities and Exchange
Commission ("SEC") under the Act with respect to the offering of the Shares
pursuant to the proposed merger with Bancwest Financial Corporation, a
Washington corporation and bank holding company ("BFC").

        In connection with the offering of the Shares, we have examined: (a) the
Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 10,
1998, among USBN, BFC and the Bank of the West, the subsidiary of BFC, attached
as Appendix A to the Prospectus/Joint Proxy Statement included in the
Registration Statement; (b) the Registration Statement; and (c) such other
documents as we have deemed necessary to form the opinion expressed below. As to
various questions of fact material to such opinion, where relevant facts were
not independently established, we have relied upon statements of officers of
USBN.

        Based and relying solely upon the foregoing, we advise you that in our
opinion, the Shares, or any portion thereof, when issued pursuant to the Merger
Agreement after the Registration Statement has become effective under the Act,
will be validly issued under the laws of the State of Washington and will be
fully paid and nonassessable.

        Consent is hereby given to the filing of this opinion as an exhibit to
the Registration Statement and to the legal reference to this firm under the
caption "Certain Legal Matters" as having passed upon the validity of the
Shares. This consent shall not be construed to cause us to be in the category of




<PAGE>   2


December 15, 1998
Page 2

persons whose consent is required to be filed pursuant to Section 7 of the Act,
or the rules and regulations of the SEC promulgated under the Act.

                                       Very truly yours,

                                       GRAHAM & DUNN PC

                                       /s/ GRAHAM & DUNN PC
§ 317.2 List of qualifying pathogens that have the potential to pose a serious threat to public health. The term “qualifying pathogen” in section 505E(f) of the Federal Food, Drug, and Cosmetic Act is defined to mean any of the following: ( a ) *Acinetobacter* species.
( b ) *Aspergillus* species.
( c ) *Burkholderia cepacia* complex.
( d ) *Campylobacter* species.
( e ) *Candida* species.
( f ) *Clostridium difficile.*
( g ) *Coccidioides* species.
( h ) *Cryptococcus* species.
( i ) Enterobacteriaceae.
( j ) *Enterococcus* species.
( k ) *Helicobacter pylori.*
( l ) *Mycobacterium tuberculosis* complex.
( m ) *Neisseria gonorrhoeae.*
( n ) *Neisseria meningitidis.*
( o ) Non-tuberculous mycobacteria species.
( p ) *Pseudomonas* species.
( q ) *Staphylococcus aureus.*
( r ) *Streptococcus agalactiae.*
( s ) *Streptococcus pneumoniae.*
( t ) *Streptococcus pyogenes.*
( u ) *Vibrio cholerae.*
# C_2019234EN.01000101.xml

| 11.7.2019 | EN | Official Journal of the European Union | C 234/1 |
| --- | --- | --- | --- |

11.7.2019

EN

Official Journal of the European Union

C 234/1

---

Statements relating to Directive (EU) 2019/1153 of the European Parliament and of the Council of 20 June 2019 laying down rules facilitating the use of financial and other information for the prevention, detection, investigation or prosecution of certain criminal offences, and repealing Council Decision 2000/642/JHA (1)

(2019/C 234/01)

Statement by the European Parliament on Article 9

The European Parliament regrets that, against the original proposal, the Directive does not include rules on precise deadlines and IT channels for the exchange of information between Financial Intelligence Units of different Member States. The European Parliament also regrets that the scope of application of this Article has been limited to cases of terrorism and organised crime associated with terrorism, and does not cover, as originally proposed, all types of serious criminal offences, which can also have serious detrimental effects on our societies. The European Parliament urges the Commission to re-examine this issue as part of its reports on the implementation and evaluation of this Directive and of the Anti-Money Laundering Directive, and specifically as part of its assessment under Article 21. The European Parliament will closely follow and analyse those reports and assessments and will come up with its own recommendations, if necessary.

Statement by the Commission

In relation to Article 9 of the Directive, the Commission regrets that, against its original proposal, the Directive does not include rules on precise deadlines and IT channels for the exchange of information between Financial Intelligence Units of different Member States. The Commission also regrets that the scope of application of this Article has been limited to cases of terrorism and organised crime associated with terrorism, and does not cover all types of serious criminal offences, as originally proposed. The Commission will further reflect on Financial Intelligence Unit to Financial Intelligence Unit cooperation, notably as part of its reports on the implementation of this Directive and of the Anti-Money Laundering Directive.

---

(1)  OJ L 186, 11.7.2019, p. 122.

---
§ 520.2123c Spectinomycin solution. ( a ) *Specifications.* Each milliliter of solution contains spectinomycin dihydrochloride pentahydrate equivalent to 50 milligrams (mg) spectinomycin.
( b ) *Sponsors.* See Nos. 016592, 054771, and 061133 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.600 of this chapter.
( d ) *Conditions of use in swine* — ( 1 ) *Amount.* Administer 5 mg per pound (lb) of body weight orally twice daily for 3 to 5 days.
( 2 ) *Indications for use.* For the treatment and control of porcine enteric colibacillosis (scours) caused by *E. coli* susceptible to spectinomycin in pigs under 4 weeks of age.
( 3 ) *Limitations.* Do not administer to pigs over 15 lb body weight or over 4 weeks of age. Do not administer within 21 days of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[73 FR 6607, Feb. 5, 2008, as amended at 78 FR 17596, Mar. 22, 2013; 79 FR 28828, May 20, 2014; 81 FR 22523, Apr. 18, 2016; 84 FR 8973, Mar. 13, 2019; 88 FR 14897, Mar. 10, 2023]
IN THE SUPREME COURT OF TEXAS

- - - - - - - -

NO. 20-0466

IN THE INTEREST OF J.A. & N.A., 

CHILDREN

§

§

§

§

§

§

Dallas County,

5th District.

November 13, 2020

Petitioner's petition for review, filed herein in the above numbered and styled case, 

having been duly considered, is ordered, and hereby is, denied.



I, BLAKE A. HAWTHORNE, Clerk of the Supreme Court of Texas, do hereby certify 

that the above is a true and correct copy of the orders of the Supreme Court of Texas in the case 

numbered and styled as above, as the same appear of record in the minutes of said Court under 

the date shown.

WITNESS my hand and seal of the Supreme Court of Texas, at the City of Austin, this 

the 22nd day of December, 2020.

Blake A. Hawthorne, Clerk

By Monica Zamarripa, Deputy Clerk

FILE COPY
1.
    
    I have reviewed this quarterly report on Form 10-Q for the quarter ended August 2, 2008 of
Hancock Fabrics, Inc.;2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;4.
    
    Our other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and
15d-15(f)) for the registrant and we have:
     5.
    
    Our other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to our auditors and the audit committee of our
board of directors:
    /s/ Jane F. AggersJane F. AggersPresident and Chief Executive Officer
IN THE SUPREME COURT OF THE STATE OF MONTANA

No. DA 22-0369

STATE OF MONTANA,

Plaintiff and Appellee,

v.

ERIN ELLIOT HOLCOMB,

Defendant and Appellant.

ORDER

Upon consideration of Appellant’s motion for extension of time to 

produce transcripts on appeal, and good cause appearing, Court 

Reporter Kelsey McAlpine is granted an extension of time to and 

including January 19, 2023, within which to prepare, file, and serve the 

transcripts requested on appeal.

The Clerk shall serve a copy of this Order upon the district court 

and the court reporter.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

December 1 2022

12/01/2022

Case Number: DA 22-0369
#### § 520.1326 Mebendazole and trichlorfon oral dosage forms.